Skin-Lightening Product Undergoing New Safety Assessment - Research Studies Raise Questions Of Relevance Of Animal Data for Human Use

Hydroquinone (HQ) is a chemical found in most over-the-counter skin-lightening products sold in the US. Animal testing studies have suggested that HQ might have harmful effects on patients who use skin-lightener products to treat pigment disorders; however, human epidemiology studies have not found similar effects, raising questions about the relevance of the data for human safety assessment of HQ.

A review of safety studies in Journal of Cosmetic Dermatology found that the male Fisher 344 rat is uniquely sensitive to the effects of HQ.  Male rats tested experienced moderate to severe kidney damage and kidney tumors, though similar effects were not found in females. The damaging effects of HQ in male Fisher 344 rats may be attributed to their lower capacity for detoxification of the substance. Humans have a much greater ability than rats for deactivating the potential toxicity of the substance.

Restrictions on the use of HQ in cosmetics preparations in European countries are based primarily on concerns about ochronosis, an abnormal deposition of pigment in the skin that has been reported in African countries where mixtures of depigmenting agents are used in skin-lighteners.  Similar effects have only rarely been reported in the US and other non-African countries. Restrictions on the availability of HQ-based products are included in a proposal published by the FDA on August 29, 2006.

“Hydroquinone based products have been used effectively in treating dermatologic conditions for over 50 years and there is a large body of evidence showing that dermal application of HQ is not associated with significant negative health impacts,” says Dr. John L. O’Donoghue, author of the article. “A risk -benefit approach in which all of the data available on HQ and alternatives is assessed is most likely to provide a path forward for providing optimal therapeutic benefits to patients with pigmentary changes of the skin.”

Journal of Cosmetic Dermatology publishes high quality, peer-reviewed articles on all aspects of cosmetic dermatology. Now under the editorship of Zoe Draelos - a leader in the field - Journal of Cosmetic Dermatology will strengthen the bridge between the best of cosmetic science available in industry and dermatology to bring readers the most cutting edge information. For more information, please visit www.blackwell-synergy.com/loi/jcd

Blackwell Publishing is the world’s leading society publisher, partnering with 665 medical, academic, and professional societies. Blackwell publishes over 800 journals and has over 6,000 books in print. The company employs over 1,000 staff members in offices in the US, UK, Australia, China, Singapore, Denmark, Germany, and Japan. Blackwell’s mission as an expert publisher is to create long-term partnerships with our clients that enhance learning, disseminate research, and improve the quality of professional practice.

For more information on Blackwell Publishing, please visit www.blackwellpublishing.com or www.blackwell-synergy.com.

About the Author

admin has written 6390 stories on this site.

Write a Comment

Gravatars are small images that can show your personality. You can get your gravatar for free today!

You must be logged in to post a comment.

Copyright © 2009 Medical News. All rights reserved.
Powered by WordPress.org, Custom Theme and ComFi.com Calling Card Company.
Close